First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

被引：0

作者：

Zeidan, Amer M. ^{[1
,2
]}

Westermann, Joerg ^{[3
]}

Kovacsovics, Tibor ^{[4
,5
]}

Assouline, Sarit ^{[6
]}

Schuh, Andre C. ^{[7
]}

Kim, Hee-Je ^{[8
]}

Macias, Gabriela Rodriguez ^{[9
]}

Sanford, David ^{[10
]}

Luskin, Marlise R. ^{[11
]}

Stein, Eytan M. ^{[12
]}

Malek, Kamel ^{[13
]}

Lyu, Jiaying ^{[14
]}

Stegert, Mario ^{[13
]}

Esteve, Jordi ^{[15
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Campus Virchow Clin, Charite Univ Med Ctr Berlin, Berlin, Germany

[4] Univ Utah, Salt Lake City, UT USA

[5] Huntsman Canc Inst, Salt Lake City, UT USA

[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[7] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[9] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[10] Univ British Columbia, BC Canc, Vancouver, BC, Canada

[11] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Inst BioMed Res, Shanghai, Peoples R China

[15] Hosp Clin Barcelona, Barcelona, Spain

来源：

关键词：

AML; acute myeloid leukemia; clinical trial; sabatolimab; venetoclax; azacitidine; Phase II;

D O I：

10.1016/s2152-2650(22)01303-9; 10.1016/S2152-2650(22)01303-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-484

引用

页码：S255 / S255

页数：1